Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07145229 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 8, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 4 of 38 sitesv4
  2. Study sites: 5 to 38v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 5
    • Start date changed from estimate of Aug 2025 to Aug 26, 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
Trial Details
NCT Number NCT07145229
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions
(from sponsor)		 Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Related terms Gout
Enrollment 380 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov